SHERIDAN, WYOMING – July 22, 2025 – Globus Medical, Inc. has announced a significant leadership transition, positioning its executive team for continued strategic growth in the musculoskeletal technology sector. Effective July 18, 2025, Keith Pfeil assumed the role of President and Chief Executive Officer, succeeding Daniel Scavilla, who stepped down to pursue another opportunity. Additionally, Kyle Kline was appointed Senior Vice President and Chief Financial Officer.
Leadership Shifts Focused on Strategic Growth
David C. Paul, Founder and Executive Chairman of Globus Medical, emphasized the alignment between Pfeil’s leadership style and the company’s long-term vision. “We are excited to appoint Keith Pfeil as our next President and Chief Executive Officer. Keith brings a sharp strategic mindset and a results-orientated leadership style with a clear understanding of how to drive performance across an organization,” Paul stated. “His manner and approach demonstrate strong cultural alignment with the Globus philosophy, and we look forward to him leading us as Globus continues to execute its strategy of becoming the pre-eminent musculoskeletal technology company in the world.”
Pfeil, who joined Globus in 2019 as Senior Vice President and CFO, was promoted to Executive Vice President, COO, and CFO in 2024. His leadership has been instrumental in advancing the company's strategy over the past six years. Reflecting on his new role, Pfeil commented, “I’m deeply grateful to David and the Board for this opportunity and want to thank Dan for his mentorship and partnership throughout my journey thus far at Globus. I’ve had the opportunity to grow with this team over the past 6 years, and I am excited to carry forward our strong culture of purpose, innovation and teamwork that will meaningfully impact the lives of patients as we move ahead.”
Financial Stewardship Strengthened with CFO Appointment
Kyle Kline, previously Senior Vice President of Finance, stepped into the CFO role after eight years with Globus. Pfeil highlighted their close collaboration, stating, “I’m thrilled to welcome Kyle Kline to our executive leadership team as the next CFO of Globus. After spending almost 10 years with Deloitte, Kyle joined Globus in 2017 as the Assistant Controller and has continuously taken on increased financial responsibility over his eight-year career. He and I have worked closely together, and he’s been a valued and trusted partner of mine. The combination of his integrity, passion and knowledge of our business makes him the right choice to lead Globus as its next CFO.”
Honoring a Decade of Leadership by Daniel Scavilla
Paul expressed appreciation for Scavilla’s decade of leadership at Globus, noting, “On behalf of the Board and all the employees of Globus, I want to thank Dan for his leadership and commitment to Globus over the past 10 years. Dan has helped us with our vision of transitioning Globus from an implant and instrument provider to a musculoskeletal technology and solutions provider. We are grateful for his contributions and wish him continued success in his next chapter.”
Scavilla remarked, “It has been an honor to lead Globus Medical and be part of this exceptional team. As the Company continues to move forward, I have made the decision to step down to pursue another opportunity. I look forward to watching the Company’s continued success as Keith leads Globus into its next chapter and know that he will drive meaningful impact to the Company as it moves ahead. I’m proud to have been part of Globus.”
Preliminary Q2 2025 Results Underscore Business Momentum
Globus also announced its preliminary second-quarter sales results for 2025, projecting revenues of approximately $745.3 million — an 18.4% increase over Q2 2024. Base business sales, excluding contributions from the Nevro acquisition, are estimated at $650.8 million, marking a 3.3% year-over-year growth. On a day-adjusted basis, this reflects a 4.8% increase.
Pfeil highlighted performance drivers, stating, “Our second quarter results demonstrated a significant improvement over Q1, led by our US Spine business, which grew approximately 7.4 percent on a day-adjusted basis compared to the prior year quarter, as well as notable sequential improvement in Enabling Technology sales. Our US Spine business had strong, consistent momentum throughout Q2, delivering its highest quarterly revenue result since the 2023 merger with NuVasive. Looking ahead, we seek to continue this trend, while continuing to convert our Enabling Technologies pipeline.”
Full-Year Guidance Reaffirmed
Globus reaffirmed its 2025 guidance, maintaining its revenue outlook at $2.80 to $2.90 billion with non-GAAP fully diluted EPS guidance in the range of $3.00 to $3.30. The company will report full Q2 financial results after market close on August 7, 2025.
For more information, visit www.globusmedical.com/investors.